Kevin Krause Email Address

Senior Director Corporate Development and Head of Microbiology

Achaogen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE). Plazomicin is an aminoglycoside designed to overcome clinically relevant aminoglycoside resistance mechanisms. In addition, its research and development pipeline includes two programs that specifically target Pseudomonas aeruginosa or Acinetobacter baumannii infections: a program to discover and develop small molecule inhibitors of LpxC, which is an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria, and a therapeutic antibody program. Its development plan for plazomicin includes over two Phase III clinical trials.

Entrepreneurial executive providing leadership in various businesses for 20+ years. Exceptional negotiator, recruiter and business developer. Managed, owned and grown a business into 38 countries around the world. Extensive experience in domestic and international franchising, commercial real estate, finance and contracts. In all business matters a strong emphasis is placed on lean, efficient operations, team building, communication and strategic development.